Navigation Links
Mount Sinai researchers to present studies at American Society of Clinical Oncology Meeting

(New York UNDER EMBARGO May 31, 2014) Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2014 American Society of Clinical Oncology (ASCO) meeting May 30-June 3, 2014 in Chicago, including data on new treatment approaches for thyroid, head and neck, and recurrent ovarian cancers; and new biomarkers for bile duct cancers.

Highlights of Mount Sinai research at ASCO:

  • Phase II Trial on the Combination of Bevacizumab and Irinotecan in Recurrent Ovarian Cancer (Under Embargo Until SATURDAY, MAY 31, 8:00 11:45 AM)

    In a study led by Amy Tiersten, MD, Associate Professor in the Division of Hematology and Medical Oncology and a member of the Breast Cancer Medical Oncology Program, Icahn School of Medicine at Mount Sinai, the efficacy and safety of Bevacizumab and Irinotecan in patients with recurrent ovarian cancer was observed. Researchers sought to determine how well this combination worked during and after 6 months of treatment, and to estimate the length of time the cancer did not get worse. Secondary objectives were to discover overall survival, observed response rate, duration of response, and toxicity. Of the 24 patients continuing in the study, 8 experienced a partial response, 13 remained stable with no progression of the disease and 3 progressed in their disease. The observed response rate was 27.6%, and the clinical benefit rate was 72.4%. Twelve patients had longer than 6 months of sustained response, and the median disease progression free response rate was 8.1 months. Adverse events were within the known side effects, with the most common being diarrhea, and no treatment-related deaths were observed.

    "Our findings give hope to women with recurrent, advanced-stage ovarian cancer. The combination showed encouraging results in heavily-pretreated patients with this recurrent disease," said Dr. Tiersten. "This trial proves the effectiveness of this combination, and provided valuable information on the management of side effects."

  • Molecular Profiling of Bile Duct Cancers and Gallbladder Cancers Reveals Potential Therapeutic Targets (Under Embargo Until SATURDAY, MAY 31, 8:00 11:45 AM)

    In a study led by Randall Holcombe, MD, Professor of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, distinct biomarker features in bile duct and gallbladder cancers were discovered. A total of 643 (291 intrahepatic bile duct cancer; 115 extrahepatic bile duct cancer; 237 gallbladder cancer) cases were evaluated, diagnosis collected from referring physicians, and cancers classified at intake based on pathology and clinical history. Using comprehensive biomarker analysis including protein expression and gene sequencing and amplification, researchers identified 16 gene mutations out of 45 genes. Findings suggest effective treatments for these rare and often fatal diseases may be developed.

    "The genetic mutations identified suggests potential targeted treatments in each cancer studied," said Dr. Holcombe. "This will give clinicians tailored treatment options for patients with a rare form of cancer."

  • Resiquimod Proven Safe When Used As An Adjuvant for Protein Vaccination in Melanoma Patients (Under Embargo Until SATURDAY, MAY 31, 8:00 11:45 AM)

    In a study led by researcher Rachel Sabado, PhD, Assistant Professor of Medicine, Division of Hematology and Oncology at the Icahn School of Medicine at Mount Sinai, the safety and immunogenicity of vaccination with NY-ESO-1 protein emulsified in Montanide ISA-51 VG was given with or without Resiquimod in surgically resected stage 11B-1V melanoma patients. The results of the study show that Resiquimod is safe and contributes to the induction of immune responses in patients.

    "The results of the study should prove very useful for future efforts to generate more potent cancer vaccines and provide attractive treatment alternatives for patients with a variety of NY-ESO-1 expressing cancers including melanoma for which treatment options remain limited," said Dr. Sabado.


Contact: Lucia Lee
The Mount Sinai Hospital / Mount Sinai School of Medicine

Related medicine news :

1. Mount Sinai researchers lead committee to define the clinical course of multiple sclerosis
2. Mount Sinai presents important findings at the 2014 American Urological Association Meeting
3. Mount Sinai researchers identify changes that may occur in neural circuits due to addiction
4. The power of protein at breakfast; higher amounts may deliver more benefits
5. Mount Sinai researchers find promising new drug targets for cocaine addiction
6. As Lipitor Lawsuits Mount, Bernstein Liebhard LLP Notes Publication of New Study with Possible Explanation for Link between Statins and Diabetes
7. Mount Sinai Queens Names New Orthopaedics Dept. Chief
8. Da Vinci Robot Lawsuits Mount, as Bernstein Liebhard LLP Comments on AARP Robotic Surgery Concerns
9. Bernstein Liebhard LLP Launches New Transvaginal Mesh Lawsuit Website as Claims Continue to Mount in U.S. Litigations
10. Pradaxa Lawsuits Mount, as Claims in Federal Multidistrict Litigation Exceed 2,000, Bernstein Liebhard LLP Reports
11. 2014 GoPro Mountain Games Evolves the Family Friendly Mud Run and Adds BADASS Dash Obstacle Course Race to Competition Line-Up
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one ... its iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design ... announced that it has been selected as a 2015 U.S.A. Taste Champion in the ...
(Date:12/1/2015)... ... December 01, 2015 , ... December 1, 2015—Since the start ... scientific research and discoveries, leading us to better understand the disease’s behavior. Globally, ... affected by HIV/AIDS. Mediaplanet’s cross-platform edition of “World AIDS Day” provides insight on ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... optimization of adjunctive imaging is the focus of numerous abstracts accepted for presentation ... 29-December 4, 2015. Nine abstracts highlight the use of Volpara Solutions’ quantitative ...
(Date:12/1/2015)... WA (PRWEB) , ... December 01, 2015 , ... ... today that it has been selected as a finalist in this year’s Fierce ... and FierceMobileHealthcare. Next IT Healthcare was recognized as a finalist in the category ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - ... to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, ... Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... BANGALORE, India and PITTSBURGH ... TASE: MYL) today announced that it expects to be ... developing country markets funded by international donors, TLE400 (Tenofovir ... Efavirenz 400 mg) for $99 per patient, per year. ... to develop TLE400. The significantly reduced price could generate ...
(Date:12/1/2015)... , Dec. 1, 2015 Breg, Inc ... services, announced today that it has been awarded three ... Members served by Novation will have access to improved ... bracing products and soft goods dedicated to advancing orthopedic ... The aging U.S. population, rising prevalence of chronic ...
(Date:12/1/2015)... N.J. , Dec. 1, 2015 ... against HIV/AIDS, Johnson & Johnson (NYSE: JNJ ... its Janssen Pharmaceutical Companies to significantly reduce the ... who make up 74 percent of new HIV ... Announced on World AIDS Day, these new initiatives ...
Breaking Medicine Technology: